These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 17673615)
1. Erlotinib in non-small cell lung cancer treatment: current status and future development. Gridelli C; Bareschino MA; Schettino C; Rossi A; Maione P; Ciardiello F Oncologist; 2007 Jul; 12(7):840-9. PubMed ID: 17673615 [TBL] [Abstract][Full Text] [Related]
2. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Smith J Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289 [TBL] [Abstract][Full Text] [Related]
3. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626 [TBL] [Abstract][Full Text] [Related]
4. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828 [TBL] [Abstract][Full Text] [Related]
5. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA; J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829 [TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670 [TBL] [Abstract][Full Text] [Related]
7. Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. Santarpia M; De Pas TM; Altavilla G; Spaggiari L; Rosell R Future Oncol; 2013 Mar; 9(3):327-45. PubMed ID: 23469969 [TBL] [Abstract][Full Text] [Related]
8. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Patel JD; Pasche B; Argiris A Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824 [TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636 [TBL] [Abstract][Full Text] [Related]
10. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. Farina G; Longo F; Martelli O; Pavese I; Mancuso A; Moscetti L; Labianca R; Bertolini A; Cortesi E; Farris A; Fagnani D; Locatelli MC; Valmadre G; Ardizzoia A; Tomirotti M; Rulli E; Garassino MC; Scanni A Clin Lung Cancer; 2011 Mar; 12(2):138-41. PubMed ID: 21550561 [TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Silvestri GA; Rivera MP Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869 [TBL] [Abstract][Full Text] [Related]
12. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342 [TBL] [Abstract][Full Text] [Related]
13. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Langer CJ Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461 [TBL] [Abstract][Full Text] [Related]
14. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Giaccone G; Gallegos Ruiz M; Le Chevalier T; Thatcher N; Smit E; Rodriguez JA; Janne P; Oulid-Aissa D; Soria JC Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6049-55. PubMed ID: 17062680 [TBL] [Abstract][Full Text] [Related]
15. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Wu JY; Wu SG; Yang CH; Chang YL; Chang YC; Hsu YC; Shih JY; Yang PC Lung Cancer; 2011 May; 72(2):205-12. PubMed ID: 20832137 [TBL] [Abstract][Full Text] [Related]
16. Gefitinib in the treatment of advanced non-small-cell lung cancer. Reck M Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595 [TBL] [Abstract][Full Text] [Related]
17. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib. Sandler A Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):17-22. PubMed ID: 14682119 [TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658 [TBL] [Abstract][Full Text] [Related]
19. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486 [TBL] [Abstract][Full Text] [Related]
20. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]